Oncolytics Biotech Inc T.ONC

Q4 2023 reports lower fully diluted shares vs Q3 2023

[Noteable]

The Q4 2023 reported 67,624,036 fully diluted shares outstanding versus 69,803,255 in the previously quarter (Q3 2023) - a difference of approximately 2.2 Million shares - to the long-term shareholders benefit should this down-sloping trend hold or continue.

[Noteable]

ONCY is a LATE STAGE Biotech company that has addressed manufacturing over the course of 2023 and is now going into Phase 3 registration studies, regulatory approval, and the potential near-term commercialization of pelareorep.  While early-stage biotechs focus on developing and testing their products, late-stage biotechs shift their focus to manufacturing, regulatory approval, and